phrykt

Elicio Therapeutics, Inc. (ELTX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of ELTX were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Elicio Therapeutics

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ELTX

49 funds and institutions reported ELTX shares worth $15.4M at the end of Q2 2026, about 21% of the company. The largest holder is Knoll Capital Management, LLC with 6.5%.

Funds and institutions (13F) 21%Everyone else 79%

10 largest owners, by share of the company

Knoll Capital Management, LLC6.5%
BlackRock, Inc.4.1%
Vanguard Capital Management LLC3.1%
Geode Capital Management, LLC1.7%
State Street Corp1.0%
Northern Trust Corp0.7%
Ikarian Capital, LLC0.5%
Vanguard Portfolio Management LLC0.5%
Vanguard Fiduciary Trust Co0.5%
Alliancebernstein L.P.0.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Knoll Capital Management, LLC1.21M6.48%$4.7M+92%
BlackRock, Inc.766,0054.10%$3M+1414%
Vanguard Capital Management LLC572,1513.06%$2.2M+10%
Geode Capital Management, LLC311,3541.66%$1.2M+130%
State Street Corp179,4200.96%$702K+254%
Northern Trust Corp130,1620.70%$509K+118%
Ikarian Capital, LLC100,0000.53%$391KNew
Vanguard Portfolio Management LLC88,9050.48%$348KNew
Vanguard Fiduciary Trust Co88,0620.47%$344K+27%
Alliancebernstein L.P.81,2800.43%$318KNew
UBS Group AG40,4190.22%$158K+20%
Charles Schwab Investment Management Inc31,7060.17%$124KNew
Sixth Street Partners Management Company, L.P.31,7060.17%$124KNew
Boothbay Fund Management, LLC30,6900.16%$120KNew
Morgan Stanley25,5460.14%$99.9K-21%
Leonteq Securities AG20,0000.11%$78.2KNew
Nuveen, LLC17,8880.10%$69.9KNew
Citigroup Inc17,7260.09%$69.3KNew
Bank of New York Mellon Corp15,8840.08%$62.1KNew
New York State Common Retirement Fund14,2000.08%$55.5KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No ELTX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ELTX short interest

Moderate short interest. 7.0% of ELTX shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 6%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.84M ELTX shares were sold short, 7.0% of the shares outstanding, up 7.8% from the report before. At the average daily volume of 313,093 shares, buying them all back would take about 5.9 trading days (days to cover).

Shares short, % of all shares

6.99%May 15Oct 3011.1%

Days to cover

5.9May 15Oct 3017.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.84M6.99%+8%313,0935.9
Oct 15, 20261.70M6.48%+10%234,7327.3
Sep 30, 20261.55M5.91%-7%377,0474.1
Sep 15, 20261.67M6.34%+5%375,0174.4
Aug 31, 20261.58M6.03%-6%299,4435.3
Aug 14, 20261.68M6.40%-4%248,4846.8
Jul 31, 20261.75M9.34%-7%344,7095.1
Jul 15, 20261.88M10.03%+8%1.70M1.1
Jun 30, 20261.73M9.27%-11%7.00M1.0
Jun 15, 20261.95M10.43%+3%893,5412.2
May 29, 20261.90M10.14%+9%127,39914.9
May 15, 20261.74M9.30%+5%142,49312.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Elicio Therapeutics company events

Elicio Therapeutics filed 10 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 14, 2026AnnouncementOf this Current Report on Form 8-K “Notice of Annual Meeting” is incorporated by reference into this Item 5.08. Filing
  3. Aug 13, 2026ResultsReleased financial results. Filing
  4. Jul 2, 2026AgreementElicio Therapeutics, Inc., a Delaware corporation, entered into a Securities Purchase Agreement with certain institutional investors (each an “Investor” and, collectively, the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company… Filing
  5. Jun 24, 2026AnnouncementShared information with investors. Filing
  6. Jun 17, 2026AnnouncementElicio Therapeutics, Inc. issued a press release announcing preliminary clinical observations which the Company believes support the evaluation of ELI-002 7P in combination with checkpoint inhibition as well as the Company’s plans to conduct a Phase 1 study in first-line metastatic mutant KRAS… Filing
  7. Jun 15, 2026AnnouncementElicio Therapeutics, Inc. issued a press release announcing the results from the Company’s randomized Phase 2 AMPLIFY-7P study in adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma and outlining the Company’s refined Phase 3 development strategy for ELI-002 7P. A copy of the press release… Filing
  8. May 11, 2026ResultsReleased financial results. Filing
  9. Mar 16, 2026AgreementElicio Therapeutics, Inc. entered into an At Market Issuance Sales Agreement with B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. with respect to an at-the-market offering program under which the Company may issue and sell, from time to time at… Filing
  10. Mar 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Elicio Therapeutics financials

Famous investors that hold ELTX

3 of the 50 well-known investors we track reported holding ELTX in their latest 13F filing. The largest position is Ken Griffin's, worth $989K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026543,450$989K0.0%New
Jim Simons · Renaissance TechnologiesQ3 2026160,550$292K0.0%New
Israel Englander · Millennium ManagementQ3 202614,385$26.2K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Elicio Therapeutics, Inc. (ELTX) stock

Who owns the most ELTX stock?

The largest reported owner of Elicio Therapeutics, Inc. (ELTX) is Knoll Capital Management, LLC, with 6.5% of the company. In total, 49 funds and institutions reported holding ELTX at the end of Q2 2026, together about 21% of the shares. See the largest owners.

Are ELTX insiders buying or selling?

No ELTX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in ELTX?

As of Oct 30, 2026, 1.84M ELTX shares were sold short, 7.0% of the shares outstanding, up 7.8% from the report before. At the average daily volume of 313,093 shares, buying them all back would take about 5.9 trading days (days to cover). See the history.

Which famous investors hold ELTX?

3 of the 50 well-known investors we track reported ELTX in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $989K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.